| QB3@953 companies raise $1.36Bn in 1st 3 years!|
In just over 3 years, QB3@953 companies have attracted $1.36Bn in investments and acquisitions. Many of these startups began with little more than a single bench and a dream and now they are changing the world - think Alector, Assembly Biosciences, Cell Design Labs, Delinia, Ripple Foods, Symic, and many more. We are so proud to have been able to enable awesome so many times. Press release
| OneSkin closes $2M Financing to reverse aging skin|
OneSkin Technologies is working on optimizing their technology of in vitro tissue aging and quantitative measurement of anti-aging molecule effects over the age of skin models. This platform will allow them to screen for molecules that molecules that truly rejuvenate skin or prevent aging.
| New Core Equipment: GE WAVE 25 |
The WAVE 25 bioreactor system will allow QB3@953 startups to reliably and repeatedly grow up to 25L of cells for protein production. The single use bags standardize production and eliminates the need for clean-rooms, all of which saves time and money.
We are dedicated to helping our researchers get reliable data fast - and the Wave system is a perfect complement to this philosophy.
Jonah Nebrida, GE Field Application Scientist, will be holding our first training session on May 30 from 9:30 - 12:30 PM. Registration
| OneSkin Technologies|
OneSkin Technologies believes in the power of data and technology to fight our oldest enemy - aging. Aging is the major risk factor for many modern diseases and the skin is one of the most affected organs. We are harnessing the most advanced tools in tissue engineering and molecular biology to find molecules able to truly reverse skin aging. Our unique platform combines real human skin models and molecular markers to discover and produce the first generation of molecules for personalized anti-aging skincare products, scientifically proved for preventing or reverse aging.
| Alaunus Biosciences|
Alaunus Biosciences is a preclinical-stage immune-oncology company using a proprietary technology platform to address unmet clinical needs in cancer diagnosis and treatment. They take advantage of the unique protease activity signature present in the tumor microenvironment, and leverage it to develop protease-activated cancer therapeutics and protease-based prognostic biomarkers. They are initially focusing their technology on developing a laboratory-based assay for risk stratification and early detection of pancreatic cancer, by identifying pre-malignant cysts in the pancreas before they develop into full tumors.
| Lunch Seminar: May 4, 12:00 - 1:00 PM|
Effective Regulatory Strategies: Tapping into FDA Expedited Review Programs
Charles Andres, JD, PhD, RAC
Effective regulatory strategies are important success drivers for drug and medical device companies. They have several components and:
The talk will provide an introduction to four important FDA programs that are designed to help expedite drug and medical device development and market entry. These programs should always be evaluated when designing effective regulatory strategies.
- Sync seamlessly and synergistically with patent strategies;
- Realize all available U.S. Food and Drug Administration (FDA) regulatory exclusivities;
- Play a significant role in maximizing product life span (as part of lifecycle management);
- Minimize costs, resources, and time devoted to clinical development; and
- Shorten FDA review times and result in successful FDA clearance or allowance.
| Charles Andres, Ph.D., RAC, is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. He focuses on patent prosecution, strategic patent counseling, IP due diligence, drug and medical device FDA regulatory counseling, invalidity and non-infringement opinions, life-cycle management, Supreme Court and Federal Circuit amicus briefs, and related business matters.|
| Lunch Seminar: May 12, 12:30 - 1:30 PM|
Amgen Innovator Series:
Next Generation Microbial Therapeutics: Transforming the Therapeutic Landscape for Atopy & Asthma
Nikole E. Kimes, PhD
Co-Founder & VP, Siolta Therapeutics
Siolta Therapeutics is designing microbial therapeutics aimed at the prevention and treatment of inflammatory diseases. They are currently focused on the rational design of a mixed-species therapeutic microbial consortium to treat airway inflammation. Ultimately working towards a future in which the microbiome can help drive patient stratification and tailored microbial therapeutics.
| Nikole Kimes, PhD, is Co-Founder and Vice President of Siolta Therapeutics. Nikole's was trained as an environmental and human microbial ecologist - most recently as a postdoctoral scholar in the laboratory of Dr. Susan Lynch at UCSF, which provided the foundation for Siolta Therapeutics. Her efforts at Siolta leverage microbiota data to improve patient stratification and develop microbial therapeutics to re-engineer microbiome composition and metabolic function in the gastrointestinal tract.|
| Workshop: May 24, 10:00 - 11:00 AM|
Environmental Health & Safety Reporting
Virginia St. Jean, CIH
Green Programs Manager, San Francisco Department of Public Health
| Bring your laptop for environmental reporting training specifically focused for tenants of QB3@953. The workshop will cover:|
- What volumes and types of hazmats are regulated locally
- How to report in the State's online reporting system CERS (California Environmental Reporting System)
- What local inspectors expect to see on-site
- Renewal frequency vs. inspection requency
- How to stay in good compliance